

Literaturverzeichnis

zum Titelthema „S1-Leitlinie: Pädiatrische Multiple Sklerose“, von Dr. Astrid Blaschek, Professor Dr. Wolfgang Müller-Felber, Universitätsprofessor Dr. Florian Heinen und Professor Dr. Peter Huppke, Bayerisches Ärzteblatt 5/2017, Seite 200 ff.

1. Reinhardt K, Weiss S, Rosenbauer J, Gartner J, von Kries R. Multiple sclerosis in children and adolescents: incidence and clinical picture - new insights from the nationwide German surveillance (2009-2011). *Eur J Neurol* 2014;21:654-9.
2. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology* 1983;33:1444-52.
3. Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. *N Engl J Med* 2007;356:2603-13.
4. SIGN Scottish Intercollegiate Guidelines Network (SIGN) www.sign.ac.uk
5. Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M, Banwell B. Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. *Lancet neurology* 2014;13:936-48.
6. Stark W, Huppke P, Gartner J. Paediatric multiple sclerosis: the experience of the German Centre for Multiple Sclerosis in Childhood and Adolescence. *Journal of neurology* 2008;255 Suppl 6:119-22.
7. Venkateswaran S, Banwell B. Pediatric multiple sclerosis. *Neurologist* 2010;16:92-105.
8. Huppke B, Ellenberger D, Rosewich H, Friede T, Gartner J, Huppke P. Clinical presentation of pediatric multiple sclerosis before puberty. *Eur J Neurol* 2014;21:441-6.
9. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Annals of neurology* 2011;69:292-302.
10. Huppke P, Stark W, Zurcher C, Huppke B, Bruck W, Gartner J. Natalizumab use in pediatric multiple sclerosis. *Archives of neurology* 2008;65:1655-8.
11. Ghezzi A, Pozzilli C, Grimaldi LM, et al. Safety and efficacy of natalizumab in children with multiple sclerosis. *Neurology* 2010;75:912-7.
12. Huppke P, Hummel H, Ellenberger D, et al. JC virus antibody status in a pediatric multiple sclerosis cohort: prevalence, conversion rate and influence on disease severity. *Mult Scler* 2015;21:382-7.
13. Fragoso YD, Alves-Leon SV, Barreira AA, et al. Fingolimod Prescribed for the Treatment of Multiple Sclerosis in Patients Younger Than Age 18 Years. *Pediatric neurology* 2015;53:166-8.